Skip to main content
×
Home
    • Aa
    • Aa

Will people change their vector-control practices in the presence of an imperfect dengue vaccine?

  • T. M. Q. R. BOCCIA (a1), M. N. BURATTINI (a1), F. A. B. COUTINHO (a1) and E. MASSAD (a1) (a2)
  • DOI: http://dx.doi.org/10.1017/S0950268813001350
  • Published online: 05 June 2013
Abstract
SUMMARY

Human behaviours, which are influenced by social, cultural, economic and political factors, can increase or decrease the risk of dengue infection, depending on the relationship with the insect vector. Because no vaccine is currently available, the spread of dengue can only be curtailed by controlling vector populations (Aedes aegypti and others) and by protecting individuals. This study tested the hypothesis that dengue-affected populations are likely to relax their vector-control habits if a potentially protective vaccine becomes available. The hypothesis was tested using two approaches: a mathematical model designed to describe dengue transmission and an empirical field test in which the local population of an endemic area was interviewed about their vector-control habits given the presence of a theoretical vaccine. The model demonstrated that depending on the level of vector-control reduction, there is a threshold in vaccine efficacy below which it is better not to introduce the vaccine. The interview showed that people who were informed that a very effective vaccine is available would reduce their vector-control habits significantly compared to a group that was informed that the vaccine is not very effective.

Copyright
Corresponding author
*Author for correspondence: Dr E. Massad, School of Medicine, The University of São Paulo, Av. Dr Arnaldo 455, São Paulo, CEP 01246-903, SP, Brazil and LIM01 HC-FMUSP. (Email: edmassad@usp.br)
Linked references
Hide All

This list contains references from the content that can be linked to their source. For a full set of references and notes please see the PDF or HTML where available.

1.DJ Gubler . Epidemic dengue/dengue hemorrhagic fever as a public health, social and economic problem in the 21st century. Trends in Microbiology 2002; 10: 100103.

2. AWilder-Smith , DJGubler . Geographic expansion of dengue: the impact of international travel. Medical Clinics of North America 2008; 92: 13771390.

3.A Wilder-Smith , Update on dengue: epidemiology, virus evolution, antiviral drugs, and vaccine development. Current Infectious Diseases Report 2010; 12: 157164.

4.C Heintzem , M Velasco Garrido , A Kroeger . What do community-based dengue control programmes achieve? A systematic review of published evaluations. Transactions of the Royal Society of Tropical Medicine and Hygiene 2007; 101: 317325.

7. DLChao , Controlling dengue with vaccines in Thailand. PLoS Neglected Tropical Diseases 2012; 6: e1876.

8.M Amaku , L Coudeville , E Massad . Designing a vaccination strategy against dengue. Revista do Instituto de Medicina Tropical de Sao Paulo 54 (Suppl. 18): S18S21.

10. EMassad , Modeling the impact of imperfect HIV vaccines on the incidence of the infection. Mathematical and Computer Modelling 2001; 34: 345351.

12. MNBurattini , Modelling the control strategies against dengue in Singapore. Epidemiology and Infection 2008; 136: 309319.

13.FAB Coutinho , Threshold conditions for a non-autonomous epidemic system describing the population dynamics of dengue. Bulletin of Mathematical Biology 2006; 68: 22632282.

14.LF Lopez , Threshold conditions for infection persistence in complex host-vector interactions. Compte Rendus Biologies 2002; 325: 10731084.

16.M Bland . An Introduction to Medical Statistics, 3rd edn. Oxford: Oxford University Press, 2000.

17.E Massad , MN Burattini , NRS Ortega . Fuzzy logic and measles vaccination: designing a control strategy. International Journal of Epidemiology 1999; 28: 550557.

19. ESMoreno and the Yellow Fever Working Group. Reemergence of yellow fever: detection of transmission in the state of São Paulo, Brazil. Revista da Sociedade Brasileira de Medicina Tropical 2011; 44: 290296.

21.N Kanesa-thasan , Safety and immunogenicity of attenuated dengue virus vaccines (Aventis Pasteur) in human volunteers. Vaccine 2001; 19: 31793188.

22.A Sabchareon , Protective efficacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: a randomised, controlled phase 2b trial. Lancet 2012; 380: 15591567.

Recommend this journal

Email your librarian or administrator to recommend adding this journal to your organisation's collection.

Epidemiology & Infection
  • ISSN: 0950-2688
  • EISSN: 1469-4409
  • URL: /core/journals/epidemiology-and-infection
Please enter your name
Please enter a valid email address
Who would you like to send this to? *
×

Keywords: